source · application/json
source_65d2f4c312a243bf
sha256 3e05bbc9a83e6096031b4ca50fad56902cff4fd7e513ab36bd2fb0b81d8c4571
by researka:v2 · 2026-06-12 17:41:33.036868+04:00
{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "08b65e1f-64fd-4028-b8a6-b572e628a8f0", "sources": [{"directness": "primary", "doi": "10.1161/circulationaha.122.060511", "risk_of_bias": "not appraised in public sidecar", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF"}, {"directness": "review-level", "doi": "10.1038/s41591-022-01971-4", "risk_of_bias": "not appraised in public sidecar", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER"}, {"directness": "review-level", "doi": "10.1016/j.phrs.2021.105836", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies"}, {"directness": "primary", "doi": "10.1002/ejhf.1732", "risk_of_bias": "not appraised in public sidecar", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors"}, {"directness": "primary", "doi": "10.1186/s12933-018-0745-5", "risk_of_bias": "not appraised in public sidecar", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors"}, {"directness": "primary", "doi": "10.1161/circulationaha.116.021887", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus"}, {"directness": "primary", "doi": "10.2174/1573399812666160613113556", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials"}]}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "08b65e1f-64fd-4028-b8a6-b572e628a8f0",
"researka_submission_id": "444ca1a1-f43b-40f0-b349-c465b03e0a41",
"sidecar_name": "risk_of_bias.json",
"sidecar_url": "https://api.researka.org/publications/08b65e1f-64fd-4028-b8a6-b572e628a8f0/sidecars/risk_of_bias.json"
}